ANIP
Price
$69.12
Change
-$0.57 (-0.82%)
Updated
Mar 28, 1:53 PM EST
42 days until earnings call
EBS
Price
$2.54
Change
-$0.06 (-2.31%)
Updated
Mar 28, 6:59 PM EST
28 days until earnings call
Ad is loading...

Compare trend and price ANIP vs EBS

Header iconANIP vs EBS Comparison
Open Charts ANIP vs EBSBanner chart's image
ANI Pharmaceuticals
Price$69.12
Change-$0.57 (-0.82%)
Volume$1.65K
CapitalizationN/A
Emergent Biosolutions
Price$2.54
Change-$0.06 (-2.31%)
Volume$370.31K
CapitalizationN/A
View a ticker or compare two or three
ANIP vs EBS Comparison Chart

Loading...

ANIPDaily Signal changed days agoGain/Loss if shorted
 
Show more...
EBSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ANIP vs. EBS commentary
Mar 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIP is a Hold and EBS is a StrongBuy.

COMPARISON
Comparison
Mar 28, 2024
Stock price -- (ANIP: $69.64 vs. EBS: $2.54)
Brand notoriety: ANIP and EBS are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ANIP: 65% vs. EBS: 10%
Market capitalization -- ANIP: $1.47B vs. EBS: $135.21M
ANIP [@Pharmaceuticals: Other] is valued at $1.47B. EBS’s [@Pharmaceuticals: Other] market capitalization is $135.21M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.16B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANIP’s FA Score shows that 0 FA rating(s) are green whileEBS’s FA Score has 1 green FA rating(s).

  • ANIP’s FA Score: 0 green, 5 red.
  • EBS’s FA Score: 1 green, 4 red.
According to our system of comparison, EBS is a better buy in the long-term than ANIP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANIP’s TA Score shows that 3 TA indicator(s) are bullish while EBS’s TA Score has 7 bullish TA indicator(s).

  • ANIP’s TA Score: 3 bullish, 5 bearish.
  • EBS’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, EBS is a better buy in the short-term than ANIP.

Price Growth

ANIP (@Pharmaceuticals: Other) experienced а +2.17% price change this week, while EBS (@Pharmaceuticals: Other) price change was +2.63% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +9.14%. For the same industry, the average monthly price growth was +5.82%, and the average quarterly price growth was +14.04%.

Reported Earning Dates

ANIP is expected to report earnings on May 09, 2024.

EBS is expected to report earnings on Apr 25, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (+9.14% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for ANIP with price predictions.
OPEN
A.I.dvisor published
a Summary for EBS with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ANIP($1.47B) has a higher market cap than EBS($135M). ANIP has higher P/E ratio than EBS: ANIP (81.93) vs EBS (17.73). ANIP YTD gains are higher at: 26.297 vs. EBS (5.625). ANIP has higher annual earnings (EBITDA): 107M vs. EBS (-518.2M). ANIP has more cash in the bank: 221M vs. EBS (112M). ANIP has less debt than EBS: ANIP (286M) vs EBS (860M). EBS has higher revenues than ANIP: EBS (1.02B) vs ANIP (487M).
ANIPEBSANIP / EBS
Capitalization1.47B135M1,087%
EBITDA107M-518.2M-21%
Gain YTD26.2975.625467%
P/E Ratio81.9317.73462%
Revenue487M1.02B48%
Total Cash221M112M197%
Total Debt286M860M33%
FUNDAMENTALS RATINGS
ANIP vs EBS: Fundamental Ratings
ANIP
EBS
OUTLOOK RATING
1..100
188
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
86100
SMR RATING
1..100
8598
PRICE GROWTH RATING
1..100
3864
P/E GROWTH RATING
1..100
8018
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (66) in the Biotechnology industry is in the same range as ANIP (95) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to ANIP’s over the last 12 months.

ANIP's Profit vs Risk Rating (86) in the Pharmaceuticals Other industry is in the same range as EBS (100) in the Biotechnology industry. This means that ANIP’s stock grew similarly to EBS’s over the last 12 months.

ANIP's SMR Rating (85) in the Pharmaceuticals Other industry is in the same range as EBS (98) in the Biotechnology industry. This means that ANIP’s stock grew similarly to EBS’s over the last 12 months.

ANIP's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as EBS (64) in the Biotechnology industry. This means that ANIP’s stock grew similarly to EBS’s over the last 12 months.

EBS's P/E Growth Rating (18) in the Biotechnology industry is somewhat better than the same rating for ANIP (80) in the Pharmaceuticals Other industry. This means that EBS’s stock grew somewhat faster than ANIP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANIPEBS
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
67%
MACD
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 11 days ago
74%
Declines
ODDS (%)
Bearish Trend 14 days ago
71%
Bearish Trend 7 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Ad is loading...
ANIPDaily Signal changed days agoGain/Loss if shorted
 
Show more...
EBSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PMYYX39.69N/A
N/A
Putnam Core Equity Fund Y
USTCX24.38N/A
N/A
Victory Science & Technology Class A
DFSGX24.10N/A
N/A
DF Dent Small Cap Growth Institutional
LTAGX14.04N/A
N/A
Lord Abbett International Growth R5
AILLX22.98N/A
N/A
Aristotle Core Equity I-2

ANIP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANIP has been loosely correlated with DRRX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIP jumps, then DRRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANIP
1D Price
Change %
ANIP100%
+0.13%
DRRX - ANIP
42%
Loosely correlated
+5.51%
SNDL - ANIP
31%
Poorly correlated
+10.66%
SCTL - ANIP
29%
Poorly correlated
N/A
PRPH - ANIP
29%
Poorly correlated
-0.48%
VTRS - ANIP
27%
Poorly correlated
+1.98%
More